Head-To-Head Survey: Crescent Biopharma (NASDAQ:CBIO) vs. Swedish Orphan Biovitrum (OTCMKTS:BIOVF)

Crescent Biopharma (NASDAQ:CBIO) and Swedish Orphan Biovitrum (OTCMKTS:BIOVF) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, earnings, risk, valuation, institutional ownership, dividends and analyst recommendations.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Crescent Biopharma and Swedish Orphan Biovitrum, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Crescent Biopharma	1	1	2	2	2.83
Swedish Orphan Biovitrum	0	3	4	0	2.57

Crescent Biopharma presently has a consensus target price of $29.60, indicating a potential upside of 41.76%. Given Crescent Biopharma’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Crescent Biopharma is more favorable than Swedish Orphan Biovitrum.

Valuation and Earnings

This table compares Crescent Biopharma and Swedish Orphan Biovitrum”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Crescent Biopharma	$10.84 million	71.54	-$153.94 million	($6.72)	-3.11
Swedish Orphan Biovitrum	$2.89 billion	5.94	$48.85 million	$0.45	106.95

Swedish Orphan Biovitrum has higher revenue and earnings than Crescent Biopharma. Crescent Biopharma is trading at a lower price-to-earnings ratio than Swedish Orphan Biovitrum, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Crescent Biopharma and Swedish Orphan Biovitrum’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Crescent Biopharma	N/A	-101.50%	-86.86%
Swedish Orphan Biovitrum	4.74%	17.72%	9.27%

Volatility & Risk

Crescent Biopharma has a beta of 1.24, indicating that its share price is 24% more volatile than the S&P 500. Comparatively, Swedish Orphan Biovitrum has a beta of 0.33, indicating that its share price is 67% less volatile than the S&P 500.

Insider and Institutional Ownership

75.2% of Crescent Biopharma shares are held by institutional investors. 24.8% of Crescent Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Swedish Orphan Biovitrum beats Crescent Biopharma on 8 of the 15 factors compared between the two stocks.

About Crescent Biopharma

Crescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.

About Swedish Orphan Biovitrum

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still’s disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company also provides other products, such as Akynzeo, Tegsedi, Jyseleca, Kepivance, Aloxi, and Waylivra. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Sanofi, Apellis Pharmaceuticals Inc., ADC Therapeutics SA, and Cartesian Therapeutics, Inc. Swedish Orphan Biovitrum AB (publ) was incorporated in 1939 and is headquartered in Solna, Sweden.